FEDERAL COURT OF AUSTRALIA
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2012] FCA 239
Citation: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2012] FCA 239 Parties: OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY v GENERIC HEALTH PTY LTD (ACN 110 617 859) File number(s): NSD 121 of 2012 Judge: YATES J Date of judgment: 16 March 2012 Catchwords: PATENTS – application for interlocutory injunctions – threatened supply of generic pharmaceutical products – imminent listing of products in the Pharmaceutical Benefits Scheme Schedule – whether prima facie case of infringement – whether balance of convenience and justice favours the grant of interlocutory injunctive relief – whether undertakings should be accepted in lieu of interlocutory injunctive relief
PATENTS – discussion of meaning of “exploit” as used in s 13 of the Patents Act 1990 (Cth) – “Swiss-style” claims – discussion whether claimed invention is a method or process
PATENTS – method of treatment claims – infringement by supply – discussion whether generic pharmaceutical product a staple commercial product – whether instructions or inducement given to use the product in a claimed method of treatment
PATENTS – “Gillette defence” – discussion whether a separate and discrete defence under the Patents Act 1990 (Cth)
Legislation: Patents Act 1990 (Cth) ss 7, 13, 18, 117, 138 and Sch 1 Cases cited: Aktiebolaget Hassle v Biochemie Australia Pty Ltd (2003) 57 IPR 1
Appleton Papers Inc v Tomasetti Paper Pty Ltd [1983] 3 NSWLR 208
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520
Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57
Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618
Bristol-Myers Squibb Co v Baker Norton Pharmaceuticals Inc [1999] RPC 253
Bristol-Myers Squibb Co v Baker Norton Pharmaceuticals Inc [2001] RPC 1
Castlemaine Tooheys Ltd v South Australia (1986) 161 CLR 148
Eli Lilly Canada Inc v Apotex Inc and the Minister of Health (2008) 75 IPR 625
Gillette Safety Razor Company v Anglo-American Trading Company Ld (1913) 30 RPC 465
Hexal Australia Pty Ltd v Roche Therapeutics Inc (2005) 66 IPR 325
Interpharma Pty Ltd v Commissioner of Patents (2008) 79 IPR 261
John Wyeth & Brother Ltd’s Application [1985] RPC 545
McCarty v The Council of the Municipality of North Sydney (1918) 18 SR (NSW) 210
Northern Territory v Collins (2008) 235 CLR 619
Pharmaceutical Management Agency Ltd v Commissioner of Patents [2000] 2 NZLR 529
Pharmacia Italia SpA v Interpharma Pty Ltd (2005) 67 IPR 397
R v MacFarlane; Ex Parte O’Flanagan and O’Kelly (1923) 32 CLR 518
Re Eisai’s Application – Second Medical Indication [1985] OJ EPO 64
Samsung Electronics Co Limited v Apple Inc [2011] FCAFC 156
Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3) (2011) 196 FCR 1
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (2009) 81 IPR 339
Tidy Tea Ltd & Lyons Tetley Ltd v Unilever Australia Ltd (1995) 32 IPR 405
Woodbridge Foam Corporation v AFCO Automotive Foam Components Pty Ltd (2002) 58 IPR 56
Keep reading for free
Create a free CaseChat account to read Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2012] FCA 239
- Decision Date
CaseChat Overview and Summary
The legal issues before the court included whether there was a prima facie case of patent infringement, and whether the balance of convenience and justice favoured the grant of interlocutory injunctive relief. The court also considered whether certain undertakings offered by the respondents could be accepted in lieu of interlocutory injunctive relief. The meaning of "exploit" as used in section 13 of the Patents Act 1990 (Cth) was also discussed, as was whether the claimed invention was a method or process. The court further considered whether the generic pharmaceutical product was a staple commercial product and whether instructions or inducements were given to use the product in a claimed method of treatment. The "Gillette defence" was also discussed as a possible defence under the Patents Act 1990 (Cth).
The court found that there was a prima facie case of patent infringement, and that the balance of convenience and justice favoured the grant of interlocutory injunctive relief. The court held that the meaning of "exploit" in section 13 of the Patents Act 1990 (Cth) encompassed the commercial manufacture, use or sale of a patented invention. The court found that the claimed invention was a method or process for the treatment of schizophrenia, and that the generic pharmaceutical product was not a staple commercial product. The court also held that the respondents had given instructions or inducements to use the product in a claimed method of treatment, and that the "Gillette defence" was not a separate and discrete defence under the Patents Act 1990 (Cth). The court ultimately found that the respondents’ undertakings were not acceptable, and granted the interlocutory injunctions sought by the applicants.
The final orders of the court required the parties to bring in draft orders giving effect to the reasons of the court.
Orders
Orders of the court
1. The parties are to bring in draft orders giving effect to these reasons.
Background
Background to the litigation
Decision
Reasons for decision
1. Whether a prima facie case of patent infringement has been made out by Otsuka against GH.
2. Whether the balance of convenience and justice favours the grant of interlocutory injunctive relief to Otsuka.
3. Whether the meaning of "exploit" as used in s 13 of the Patents Act 1990 (Cth) applies to the claimed invention.
4. Whether the claimed invention is a method or process for the purposes of patentability.
5. Whether the generic pharmaceutical product supplied by GH constitutes a staple commercial product for the purposes of infringement by supply.
6. Whether instructions or inducement were given to use the generic pharmaceutical product in a claimed method of treatment.
7. Whether the "Gillette defence" constitutes a separate and discrete defence under the Patents Act 1990 (Cth).
Held
1. The court found that Otsuka had made out a prima facie case of patent infringement against GH.
2. The balance of convenience and justice favoured the grant of interlocutory injunctive relief to Otsuka.
3. The meaning of "exploit" as used in s 13 of the Patents Act 1990 (Cth) applies to the claimed invention.
4. The claimed invention is a method or process for the purposes of patentability.
5. The generic pharmaceutical product supplied by GH does not constitute a staple commercial product for the purposes of infringement by supply.
6. There were no instructions or inducement given to use the generic pharmaceutical product in a claimed method of treatment.
7. The "Gillette defence" does not constitute a separate and discrete defence under the Patents Act 1990 (Cth).
Ratio Decidendi
Legal Principle Established
The Court considered the evidence and submissions made by both parties and found that Otsuka had made out a prima facie case of patent infringement against GH. The Court noted that GH was planning to supply its generic pharmaceutical products, which were likely to infringe the patents held by Otsuka, imminently upon their listing in the Pharmaceutical Benefits Scheme Schedule. The Court was satisfied that the balance of convenience and justice favoured the grant of interlocutory injunctive relief to Otsuka to prevent GH from supplying the infringing products before the final hearing of the case.
In addressing the meaning of "exploit" as used in s 13 of the Patents Act 1990 (Cth), the Court referred to the principles established in earlier cases and concluded that the term applied to the claimed invention in this case. The Court also found that the claimed invention was a method or process for the purposes of patentability, and that it was not limited to a physical product or apparatus.
The Court found that the generic pharmaceutical product supplied by GH did not constitute a staple commercial product for the purposes of infringement by supply, as it was specifically intended for use in the claimed method of treatment. The Court also noted that there were no instructions or inducement given to use the generic pharmaceutical product in a claimed method of treatment.
Lastly, the Court considered the "Gillette defence" and found that it did not constitute a separate and discrete defence under the Patents Act 1990 (Cth). The Court held that the defence was an aspect of the general defence of non-infringement, and did not provide a separate basis for relief. The ratio decidendi of this decision lies in the application of the principles of patent law to the specific facts of the case, and the Court's interpretation of the relevant statutory provisions. The Court followed established authority in its analysis of the meaning of "exploit" and the nature of the claimed invention, while distinguishing the "Gillette defence" from other forms of non-infringement defences.